Copyright
©The Author(s) 2021.
World J Clin Oncol. May 24, 2021; 12(5): 323-334
Published online May 24, 2021. doi: 10.5306/wjco.v12.i5.323
Published online May 24, 2021. doi: 10.5306/wjco.v12.i5.323
Figure 1 Graphical summary of different responses to immunotherapy.
Pseudoprogression: increase of longest diameter > 20% at first follow-up, followed by a decrease of > 30% at subsequent follow-up. Dissociated response: increase of some target lesions of > 20% and reduction of at least another target lesion > 30% at follow-up. Hyperprogression: significant increase of target lesion at first follow-up; a baseline study is needed to correctly assess the hyperprogression. T: Time; TV: Tumor volume.
- Citation: Ippolito D, Maino C, Ragusi M, Porta M, Gandola D, Franzesi CT, Giandola TP, Sironi S. Immune response evaluation criteria in solid tumors for assessment of atypical responses after immunotherapy. World J Clin Oncol 2021; 12(5): 323-334
- URL: https://www.wjgnet.com/2218-4333/full/v12/i5/323.htm
- DOI: https://dx.doi.org/10.5306/wjco.v12.i5.323